EBR Systems Inc (ASX: EBR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
EBR Systems Inc Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
EBR Systems Inc (ASX: EBR)
Latest News
Small Cap Shares
'Plenty of upside': 2 ASX small-cap shares to buy while they're cheap
Share Fallers
Why Collins Foods, EBR, Gold Road, and Woodside shares are dropping today
Share Gainers
Why Bigtincan, EBR, Gentrack, and New Hope shares are storming higher
Healthcare Shares
Do ASX biotech shares offer 'good buying' after the sell-off? Experts weigh in
EBR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About EBR Systems Inc
EBR Systems Inc is engaged in treatment for patients suffering from cardiac rhythm diseases by developing therapies using wireless cardiac stimulation. The company's Wise CRT System uses proprietary wireless technology to deliver pacing stimulation directly inside of the left ventricle of the heart.
EBR Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
27 Mar 2024 | $0.78 | $-0.07 | -8.28% | 75,072 | $0.82 | $0.84 | $0.78 |
26 Mar 2024 | $0.85 | $0.02 | 2.42% | 71,661 | $0.84 | $0.85 | $0.82 |
25 Mar 2024 | $0.83 | $-0.02 | -2.38% | 12,173 | $0.84 | $0.84 | $0.82 |
22 Mar 2024 | $0.84 | $0.04 | 5.00% | 231,391 | $0.80 | $0.85 | $0.78 |
21 Mar 2024 | $0.80 | $0.01 | 1.27% | 94,229 | $0.78 | $0.80 | $0.77 |
20 Mar 2024 | $0.79 | $-0.02 | -2.48% | 41,044 | $0.80 | $0.80 | $0.78 |
19 Mar 2024 | $0.81 | $0.02 | 2.53% | 126,254 | $0.79 | $0.82 | $0.78 |
18 Mar 2024 | $0.79 | $0.05 | 6.71% | 50,860 | $0.76 | $0.80 | $0.76 |
15 Mar 2024 | $0.75 | $0.03 | 4.17% | 75,396 | $0.72 | $0.76 | $0.71 |
14 Mar 2024 | $0.72 | $-0.03 | -4.03% | 317,758 | $0.78 | $0.78 | $0.70 |
13 Mar 2024 | $0.75 | $-0.06 | -7.50% | 135,964 | $0.80 | $0.80 | $0.74 |
12 Mar 2024 | $0.80 | $-0.02 | -2.44% | 163,869 | $0.80 | $0.82 | $0.80 |
11 Mar 2024 | $0.82 | $0.01 | 1.23% | 18,969 | $0.82 | $0.82 | $0.82 |
08 Mar 2024 | $0.82 | $-0.02 | -2.41% | 124,212 | $0.80 | $0.83 | $0.80 |
07 Mar 2024 | $0.83 | $0.02 | 2.47% | 51,011 | $0.81 | $0.83 | $0.79 |
06 Mar 2024 | $0.81 | $0.00 | 0.00% | 31,463 | $0.82 | $0.82 | $0.81 |
05 Mar 2024 | $0.81 | $-0.02 | -2.41% | 31,715 | $0.83 | $0.83 | $0.81 |
04 Mar 2024 | $0.83 | $0.03 | 3.75% | 150,244 | $0.80 | $0.85 | $0.80 |
01 Mar 2024 | $0.80 | $-0.02 | -2.44% | 55,107 | $0.82 | $0.83 | $0.79 |
29 Feb 2024 | $0.82 | $0.01 | 1.24% | 1,528,473 | $0.78 | $0.83 | $0.78 |
28 Feb 2024 | $0.81 | $0.06 | 8.00% | 85,631 | $0.74 | $0.81 | $0.74 |
27 Feb 2024 | $0.75 | $0.01 | 1.34% | 20,666 | $0.76 | $0.76 | $0.75 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
15 Mar 2024 | Bronwyn Evans | Buy | 17,413 | $13,059 |
On-market trade. CDIs
|
06 Mar 2024 | Bronwyn Evans | Buy | 22,033 | $17,866 |
On-market trade.
|
27 Nov 2023 | Bronwyn Evans | Buy | 5,000 | $3,042 |
On-market trade. CDIs
|
22 Nov 2023 | Bronwyn Evans | Buy | 20,000 | $12,961 |
On-market trade. CDIs
|
11 Aug 2023 | Bronwyn Evans | Issued | 182,159 | $161,210 |
Issue of options.
|
11 Aug 2023 | Christopher Nave | Issued | 182,159 | $161,210 |
Issue of options.
|
11 Aug 2023 | Karen Drexler | Issued | 182,159 | $161,210 |
Issue of options.
|
11 Aug 2023 | Allan Will | Issued | 182,159 | $161,210 |
Issue of options.
|
11 Aug 2023 | David Steinhaus | Issued | 182,159 | $161,210 |
Issue of options.
|
11 Aug 2023 | John McCutcheon | Issued | 675,000 | $597,375 |
Issue of options.
|
11 Aug 2023 | Trevor Moody | Issued | 182,159 | $161,210 |
Issue of options.
|
25 Jul 2023 | Bronwyn Evans | Buy | 32,967 | $30,000 |
Participation in share purchase plan. CDIs
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Dr Christopher Dean Nave | Non-Executive Director | Oct 2017 |
Dr Nave has served as a Director of EBR since 2017. Dr Nave is a founder and Managing Director of Brandon Capital Partners and the CEO of the Medical Research Commercialisation Fund. Dr Nave previously served as the Director of Commercialisation at the Baker Heart Research Institute. He is currently a director of The Australian Investment Council, Azura Ophthalmics, Inc., Certa Therapeutics Pty Ltd, Global Kinetics Corporation Ltd, OccuRx Pty. Ltd., Osprey Medical, Inc. (ASX: OSP), PolyActiva Pty Ltd and Que Oncology, Inc. He was chairperson of Fibrotech Therapeutics Pty Ltd at the time of its successful sale to Shire Plc and a director of Spinifex Pharmaceuticals, Inc. at the time of its sale to Novartis International AG.
|
Ms Karen Ruth Drexler | Non-Executive Director | Oct 2021 |
Ms Drexler is a serial entrepreneur with expertise in the fields of digital health, medical devices, and diagnostics.She serves on the boards of three other public companies, Resmed, Inc. (NYSE, ASX: RMD), where she serves on the compensation and nominating and governance committees, Outset Medical Inc. (NASDAQ: OM), where she serves on the compensation and nominating and governance committees, and Tivic Health Systems (NASDAQ: TIVC) where she chairs the compensation and nominating and governance committees. She is also on the board of two private companies: VIDA Diagnostics Inc., an artificial intelligence powered lung imaging solutions company, and HUMA.ai, a leading generative AI platform for life science. She also acts as a senior strategic advisor for other early-stage companies, and spent 11 years on the board of the Keller Center for Innovation in Engineering Education at Princeton University. She is an active mentor and advisor with Astia, a global nonprofit that supports highpotential female founders. She is a founding member of Astia Angels, a network of individual investors who fund such founders, and a lead mentor with StartX, the Stanford University incubator. She is also on the Life Science and Women's Health Councils for Springboard, an accelerator for women-led technology-oriented companies.
|
Mr Allan Roger Will | Executive ChairmanExecutive Director | May 2003 |
Mr Will served as the CEO of the Company from 2011 until 2019 and has served in the role of Executive Chair since 2019. He currently serves as chair of the boards of Fractyl Health, Inc. and SetPoint Medical Corporation, and a director of Fogarty Innovation. He was also founding Managing Director of Split Rock Partners' Silicon Valley office. He was founder, chair and CEO of The Foundry. He is an inventor on more than 30 issued patents.
|
Dr Bronwyn Joy Evans | Non-Executive Director | Oct 2021 |
Dr Bronwyn Evans AM, who joined the Board in October 2021 is an experienced Director and CEO with a broad technical background across multiple industry sectors including medical technology, manufacturing and technical regulation and standards. She currently holds board roles as the Chair of Building 4.0 CRC, a Director of ACOR Consultants Pty Ltd and a Director at GME Pty Ltd. She has previously held positions as CEO of Engineers Australia and CEO of Standards Australia. She has also previously held positions in innovation initiatives, including as Chair of MT Connect and was a member of the industry 4.0 Advanced Manufacturing Forum Leadership group. She has also held various senior engineering roles, including at Cochlear and GE Healthcare.
|
Dr David Mark Steinhaus | Non-Executive Director | Oct 2021 |
Dr Steinhaus retired in 2019 as Vice President and General Manager of the Heart Failure Business for the Cardiac Rhythm and Heart Failure Division at Medtronic plc (NYSE:MDT). Dr Steinhaus joined Medtronic in 2005, after 20 years of cardiology (electrophysiology) practice. Dr Steinhaus' responsibilities at Medtronic included bringing the physician voice to CRHF, identifying future opportunities in new product development, and serving as a liaison to government agencies, professional societies and medical groups. Dr Steinhaus has been closely associated with research and academia, performing clinical studies in implantable cardiac devices and leads. He served as Chair of the Department of Cardiology, and Director of the Electrophysiology Department at the Mid America Heart Institute and St. Luke's Hospital and Director of the Electrophysiology Fellowship Program at the University of Missouri at Kansas City School of Medicine, and has instructed students in medicine since 1982. Since leaving Medtronic, he has served as a consultant and board member to multiple established and early stage medical device companies. He is currently the Executive Chairman of the board of Enopace Biomedical Ltd., a company which produces therapeutic neuromodulation devices for the treatment of heart failure.
|
Mr John Graham McCutcheon | Chief Executive OfficerPresidentExecutive Director | Jun 2019 |
Mr McCutcheon has served as President and CEO of EBR since June 2019 and is responsible for the overall management and strategic direction of EBR. He has over 35 years' experience in sales, marketing, and management of medical device companies. Prior to joining EBR, He was the President and CEO of Ceterix Orthopaedics, Inc. for nine years from 2010 to 2019. He also held CEO roles at Ventus Medical, Inc. (2009-2010) and Emphasys Medical, Inc. (2000-2009).
|
Mr Trevor John Moody | Non-Executive Director | Oct 2017 |
Mr Moody has served as a Director of EBR since 2017.He recently served as Medical Device Partner at M.H. Carnegie & Co. (from 2013 to 2022), where he made investments in medical device companies. He has also served since January 2010 as President of TM Strategic Advisors LLC, a management consultancy. He was previously a General Partner at Frazier Healthcare Ventures, a large U.S. based private equity and venture capital firm. He is currently a director of electroCore, Inc., Cardiac Dimensions Pty Ltd, Renew Medical Pty Ltd, The Brain Protection Company Pty Ltd, and CurvaFix, Inc. He also serves on the board of Angel Flight West, a not-for-profit that provides free air transport for patients requiring long distance travel for medical treatment. He was a director of Simplify Medical Pty Ltd at the time of its sale to NuVasive, Inc. (NASDAQ: NUVA). He holds a B.Eng. from the University of Southern Queensland, and a M.S. in Management from the Massachusetts Institute of Technology (Sloan School).
|
Mr Brendan Case | Company Secretary |
-
|
|
Brendan Case | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Split Rock Partners Lp | 19,732,458 | 7.29% |
MRCF3 Services (H) Pty Ltd | 18,480,532 | 6.82% |
Mrcf3 Services (Hp) Pty Ltd | 16,823,969 | 6.21% |
Carnegie Innovation Fund No 2 Lp | 14,162,839 | 5.23% |
CHV III Lp | 12,818,782 | 4.73% |
Argo Investments Limited | 9,782,633 | 3.61% |
MRCF3 Services Pty Ltd | 8,782,983 | 3.24% |
Carnegie Healthcare Fund Lp | 8,776,909 | 3.24% |
Emergent Medical Partners Ii Lp | 8,479,871 | 3.13% |
SPVC VI Llc | 6,996,473 | 2.58% |
MHC Fund Services B Pty Ltd | 6,615,306 | 2.44% |
Carnegie Venture Captial Pty Ltd | 6,175,754 | 2.28% |
MRCF3 Services (Sw) Pty Ltd(I) | 6,161,947 | 2.28% |
MRCF5 Services (Ts) Pty Ltd | 6,111,111 | 2.26% |
Mr Allan Will | 5,827,224 | 2.15% |
MRCF3 Services (Hp) Pty Ltd (I) | 4,709,239 | 1.74% |
MRCF3 Services (H) Pty Ltd (II) | 4,638,382 | 1.71% |
MRCF3 Services (Sw) Pty Ltd(II) | 4,629,630 | 1.71% |
BMYG Capital Pty Ltd | 3,316,650 | 1.22% |
OKS Clear Ltd | 3,286,270 | 1.21% |